miR‑141 and miR‑375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells

Tiryakioglu,Duygu; Bilgin,Elif; Holdenrieder,Stefan; Dalay,Nejat; Gezer,Ugur

doi:10.3892/br.2013.135

miR‑141 and miR‑375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells

Authors:
- Duygu Tiryakioglu
- Elif Bilgin
- Stefan Holdenrieder
- Nejat Dalay
- Ugur Gezer
View Affiliations

Affiliations: Department of Basic Oncology, Institute of Oncology, Istanbul University, Capa, Istanbul 34390, Turkey, Institute of Clinical Chemistry and Pharmacology, University of Bonn, D‑53105 Bonn, Germany
Published online on: July 15, 2013 https://doi.org/10.3892/br.2013.135
Pages: 802-806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have demonstrated the differential expression of miR‑141 and miR‑375 in circulation of patients with advanced/metastatic prostate cancer (PCa). The aim of this study was to investigate the regulation of miR‑141 and miR‑375 by androgens and their release into the incubation medium in relation to prostate‑specific antigen (PSA) mRNA and prostate cancer antigen 3 (PCA3). Plasma levels of these molecules were measured in a small cohort of patients with localized PCa. As an in vitro cell model we used androgen‑sensitive LNCaP cells exposed to an androgen ablation of 48 h, and then treated with dihydrotestosterone (DHT) for 24 h. Expression of the four RNA molecules was measured by quantitative polymerase chain reaction (qPCR). miR‑141 and miR‑375 were induced in a dose‑dependent manner where the median stimulation reached only 1.5‑fold at maximum. The effect of DHT on PSA mRNA (up to 30‑fold) and PCA3 (up to 195‑fold) was much more evident. With regard to the release into the incubation medium, similar results were obtained with the exception of PCA3. At the highest DHT dose (100 nM), median miR‑141 and miR‑375 release was increased 1.7‑ and 1.4‑fold (P=0.07), respectively. DHT treatment led to a significant release of PSA mRNA (up to 12‑fold) into the medium while PCA3 could not be amplified from the incubation medium. In plasma only PCA3 differed significantly between localized PCa patients and healthy subjects. In conclusion, our study provides evidence that miR‑141 and miR‑375 are increasingly released into incubation medium from androgen‑stimulated cells. However, the extent of their induction was weaker than PSA mRNA or PCA3, suggesting differential regulation by androgens.

View Figures

View References

1	Hayat MJ, Howlader N, Reichman ME and Edwards BK: Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 12:20–37. 2007. View Article : Google Scholar : PubMed/NCBI
2	Leo S, Accettura C and Lorusso V: Castration-resistant prostate cancer: targeted therapies. Chemotherapy. 57:115–127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, Samadi DB and Akhavan A: Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol. 64:681–694. 2011.PubMed/NCBI
4	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
5	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kuner R, Brase JC, Sültmann H and Wuttig D: microRNA biomarkers in body fluids of prostate cancer patients. Methods. 59:132–137. 2013. View Article : Google Scholar : PubMed/NCBI
7	Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N and Gezer U: Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 32:583–588. 2011.PubMed/NCBI
8	Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sültmann H: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 128:608–616. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T and Hamdy FC: Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 106:768–774. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS and Kantoff PW: Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 73:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
11	Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G and Visakorpi T: Androgen regulation of microRNAs in prostate cancer. Prostate. 71:604–614. 2011. View Article : Google Scholar
12	Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY and Chen XM: miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate. 72:1514–1522. 2012. View Article : Google Scholar
13	van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate. 57:205–225. 2003.PubMed/NCBI
14	Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, Neves AF, Nasciutti LE, Goulart LR and Gimba ER: PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 12:5072012. View Article : Google Scholar : PubMed/NCBI
15	Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating microRNA-141 to circulating tumor cells, lactate dehydrogenase and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 9:39–45. 2011. View Article : Google Scholar
16	Neves AF, Dias-Oliveira JD, Araújo TG, Marangoni K and Goulart LR: Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis. Clin Chem Lab Med. 51:881–887. 2012.PubMed/NCBI
17	Sun XY, Plouzek CA, Henry JP, Wang TT and Phang JM: Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res. 58:2379–2384. 1998.PubMed/NCBI
18	Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI